Sildenafil citrate in combination with tamsulosin versus tamsulosin monotherapy for management of male lower urinary tract symptoms due to benign prostatic hyperplasia: A randomised, double-blind, placebo-controlled trial
| Autor: | Mohamed M. Omran, A.M. Fawzi, Aref Maarouf, Esam Desoky, Hazem Elgalaly, Salem Khalil, Emad A. Salem, Mostafa Kamel, Ahmed Sakr |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
Tamsulosin
medicine.medical_specialty Sildenafil Urology BMI body mass index PDE5-I phosphodiesterase type 5 inhibitor 030232 urology & nephrology Placebo-controlled study Qmax maximum urinary flow rate urologic and male genital diseases law.invention 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Randomized controlled trial Lower urinary tract symptoms law medicine RCT randomised controlled trial ED erectile dysfunction NO nitric oxide Lower urinary tract symptoms (LUTS) business.industry Benign prostatic hyperplasia (BPH) Hyperplasia medicine.disease IIEF-5 five-item version of the International Index of Erectile Function questionnaire QoL quality of life Diseases of the genitourinary system. Urology OD once daily Erectile dysfunction SMD standardised mean difference chemistry 030220 oncology & carcinogenesis Original Article RC870-923 business CONSORT Consolidated Standards of Reporting Trials medicine.drug |
| Zdroj: | Arab Journal of Urology Arab Journal of Urology, Vol 15, Iss 1, Pp 53-59 (2017) |
| ISSN: | 2090-5998 2090-598X |
| Popis: | Objective: To assess the additive effect of sildenafil citrate to tamsulosin in the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia (LUTS/BPH) in men with or without erectile dysfunction (ED). Patients and methods: In all, 150 men with untreated LUTS/BPH with or without ED were randomised to receive sildenafil 25 mg once daily (OD) or placebo OD (night time) combined with tamsulosin 0.4 mg OD (day time) for 6 months. Changes from pre-treatment scores in International Prostate Symptom Score (IPSS), IPSS-quality of life (QoL) score, maximum urinary flow rate (Qmax), and the five-item version of the International Index of Erectile Function questionnaire (IIEF-5) were assessed at 3 and 6 months. Safety profiles were assessed by physical examination and monitoring clinical adverse events. Results: Group A comprised of men who received tamsulosin and sildenafil (75 men), whilst those in Group B received tamsulosin and placebo (75). The IPSS was significantly improved in Group A compared to Group B, at −29.3% vs −13.7% (P = 0.039) at 3 months and −37% vs −19.6% (P = 0.043) at 6 months after treatment. Qmax significantly improved in both groups compared with before treatment (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|